Why the study?
Do cardiovascular risk scores accurately identify the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus?
Do cardiovascular risk scores accurately identify the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus?
Traditional cardiovascular risk scores are inadequate for risk stratification in women with SLE, as they classify nearly all patients as low-risk despite the presence of subclinical coronary atherosclerosis.
Risk scores classify most SLE patients low-risk despite atherosclerosis; leaves open need for SLE-specific validation before clinical use.
The Framingham risk score is widely used to identify patients at increased cardiovascular risk, and women with systemic lupus erythematosus (SLE) have a marked increased prevalence of cardiovascular events. Thus, we examined the hypothesis that cardiovascular risk scores would identify women with SLE who had asymptomatic coronary atherosclerosis. Ninety-three women with SLE and 65 control subjects were studied. The Framingham score and a score for younger populations developed from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study were compared in both groups. Coronary atherosclerosis was ascertained by electron beam computed tomography. There were no significant differences in the median (interquartile range) Framingham [5 (2-10) compared to 7 (0-10), P = 0.88] and PDAY [15 (14-18) compared to 16 (13-18), P = 0.99] scores in patients with SLE and controls, respectively. Coronary atherosclerosis was associated with higher Framingham [12 (3-15) compared to 4 (1-8), P = 0.008] and PDAY [17 (15-19 compared to 15 (12-18), P = 0.03)] scores in patients with SLE; however, 99% of patients were classified as low-risk with a 10-year predicted risk of 1% (<1-3%). Our data indicate that cardiovascular risk scores are not adequate for risk stratification in women with SLE. Measurement of coronary calcification may add information to identify asymptomatic women with lupus who might benefit from aggressive preventive measures.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: